Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review)
Open Access
- 17 March 2022
- journal article
- review article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 25 (5) , 1-8
Abstract
Intrahepatic cholangiocarcinoma (ICC) is a primary malignant liver tumour whose incidence is second only to that of hepatocellular carcinoma. ICC is a highly heterogeneous disease arising from neoplastic transformation of intrahepatic biliary epithelial cells (cholangiocytes), and it is characterized by a very poor prognosis. Signal transducer and activator of transcription 3 (STAT3) is an important oncogene that is widely expressed in numerous cancers. STAT3 is a candidate target for the treatment of ICC. However, studies on STAT3 and the occurrence and development of ICC require improvements. Therefore, the present review summarized the mechanism of STAT3 in ICC and provided a theoretical basis for STAT3 to become an effective target for determining the prognosis and treatment of ICC.Keywords
This publication has 100 references indexed in Scilit:
- A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinasesBlood Cancer Journal, 2013
- Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapiesOncogene, 2013
- Potent and Selective Phosphopeptide Mimetic Prodrugs Targeted to the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3Journal of Medicinal Chemistry, 2011
- Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cellsHepatology, 2010
- Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?Cell Division, 2010
- Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinomaBritish Journal of Cancer, 2009
- Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survivalMolecular Cancer, 2008
- Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft miceBMC Cancer, 2007
- Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironmentNature Reviews Immunology, 2007
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004